QL301 / Qilu Pharma, QLSF Biotherapeutics - LARVOL DELTA

Safety and efficacy of a novel PD-L1/4-1BB bispecific antibody QLF31907 in previously-treated patients with advanced melanoma: Results from a phase 2 study. (ASCO 2026) - P2 | "QLF31907 showed potential anti-tumor activity and acceptable safety profile in heavily-treated pts with advanced melanoma, including IO-exposed pts. These results warrant validation in further clinical trials."

Bispecific • Clinical • Metastases • P2 data • Hepatology • Liver Failure • Melanoma • Solid Tumor

A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma. (ASCO 2024) - P1 | "QLF31907 showed an acceptable safety profile and preliminary clinical activity in heavily pretreated patients with advanced solid tumors and lymphoma. Encouraging clinical activity was observed in patients who have failed PD-1/PD-L1 therapy and further research on the mechanism is ongoing."

Clinical • Metastases • P1 data • Anemia • Cervical Cancer • Dyslipidemia • Hematological Disorders • Hematological Malignancies • Hypertriglyceridemia • Infectious Disease • Lymphoma • Melanoma • Musculoskeletal Pain • Oncology • Pain • Pneumonia • Respiratory Diseases • Solid Tumor

Qilu Pharmaceutical’s Three Clinical Studies on Cancer Immunotherapy Presented at ASCO 2024 (PRNewswire) - "The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting convened from May 31 to June 4, 2024 in Chicago, USA, adopting a hybrid format. Among the presented works, three clinical studies from Qilu Pharmaceutical were selected for poster sessions....The study, led by Professor Tongyu Lin from Sichuan Cancer Hospital, is a phase I dose-escalation/expansion trial focusing on QLF31907 (PD-1/4-1BB dual antibody) in patients with advanced solid tumors and lymphoma."

P1 data • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1/2 | N=60 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

Combination therapy • Metastases • New P1/2 trial • Oncology • Solid Tumor

A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd. | Trial completion date: Sep 2022 ➔ Jun 2024 | Trial primary completion date: Jul 2022 ➔ Mar 2024

Metastases • Trial completion date • Trial primary completion date • Esophageal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hematological Malignancies • Hepatocellular Cancer • Lung Cancer • Lymphoma • Melanoma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • MSI

Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Melanoma • Oncology • Solid Tumor • Urothelial Cancer

Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma (clinicaltrials.gov) - P2 | N=66 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

Metastases • New P2 trial • Melanoma • Oncology • Solid Tumor • Urothelial Cancer